Compare · BFRI vs NVO
BFRI vs NVO
Side-by-side comparison of Biofrontera Inc. (BFRI) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BFRI and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $174.57B, about 16119.8x BFRI ($10.8M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 6 for BFRI).
- NVO has more recent analyst coverage (25 ratings vs 3 for BFRI).
- Company
- Biofrontera Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $10.8M
- $174.57B
- 1M return
- -
- +0.27%
- 1Y return
- -
- -19.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 9
- Recent ratings
- 3
- 25
Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BFRI
- SEC Form 10-Q filed by Biofrontera Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Biofrontera Inc.
- Biofrontera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth
- Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026
- SEC Form 25-NSE filed by Biofrontera Inc.
- Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
- Biofrontera Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
- SEC Form 10-Q filed by Biofrontera Inc.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S